​

Intra-Cellular Therapies Ownership | Who Owns Intra-Cellular Therapies?

OverviewForecastRevenueFinancialsChartTranscripts

Intra-Cellular Therapies Ownership Summary

Intra-Cellular Therapies is owned by 63.39% institutional investors, 3.22% insiders, and 33.39% retail investors. Fmr is the largest institutional shareholder, holding 10.47% of ITCI shares. Fidelity Growth Compy Commingled Pl O is the top mutual fund, with 3.69% of its assets in Intra-Cellular Therapies shares.

ITCI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockIntra-Cellular Therapies63.39%3.22%33.39%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.69%10.91%62.39%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr11.08M10.47%$925.10M
Vanguard group9.72M9.19%$811.93M
Blackrock6.32M6.53%$432.97M
Blackrock funding, inc. /de6.11M5.78%$510.53M
Jpmorgan chase5.13M4.85%$428.13M
Wasatch advisors lp3.25M3.07%$271.34M
Norges bank3.21M3.04%$268.35M
Invesco3.08M2.91%$257.01M
Avoro capital advisors3.05M2.88%$254.74M
Bellevue group2.44M2.31%$203.81M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Ally bridge group (ny)147.75K10.58%$12.34M
Artia global partners lp219.72K6.56%$18.35M
Deep track capital, lp2.00M6.23%$167.04M
First turn management294.41K4.40%$24.59M
Suvretta capital management1.44M4.10%$120.19M
Dcf advisers99.76K4.03%$8.33M
Bellevue group2.44M3.92%$203.81M
Avoro capital advisors3.05M3.60%$254.74M
Silverarc capital management179.09K3.27%$14.96M
Perceptive advisors1.29M2.97%$107.60M

Top Buyers

HolderShares% AssetsChange
Norges bank3.21M0.04%3.21M
Raymond james financial915.36K0.03%915.36K
Adage capital partners gp678.00K0.10%493.00K
Timessquare capital management840.27K1.02%402.19K
Deep track capital, lp2.00M6.23%399.31K

Top Sellers

HolderShares% AssetsChange
Blackrock6.32M0.01%-1.76M
Wasatch advisors lp3.25M1.34%-599.77K
Alyeska investment group451.15K0.14%-479.98K
Price t rowe associates inc /md/589.91K0.01%-452.55K
State street1.80M0.01%-438.44K

New Positions

HolderShares% AssetsChangeValue
Norges bank3.21M0.04%3.21M$268.35M
Raymond james financial915.36K0.03%915.36K$76.45M
Driehaus capital management215.44K0.14%215.44K$14.76M
Orbimed advisors163.00K0.28%163.00K$13.61M
Ally bridge group (ny)147.75K10.58%147.75K$12.34M

Sold Out

HolderChange
Financial gravity asset management-1.00
Sanctuary wealth management-1.00
Financial synergies wealth advisors-6.00
Continuum advisory-6.00
Voisard asset management group-7.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024239-34.16%67,046,839-28.51%630.81%120-32.20%85-32.54%
Sep 30, 2024361-5.99%93,782,613-2.67%881.03%176-18.14%126-0.79%
Jun 30, 20243783.00%96,330,66610.68%991.21%21019.32%127-
Mar 31, 20243675.16%87,032,607-2.57%901.05%176-3.83%12711.40%
Dec 31, 202334915.95%89,328,8313.75%921.15%18312.96%11426.67%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl O3.90M3.69%-95.00K
Fidelity Growth Compy Commingled Pl S3.87M3.64%38.13K
Vanguard US Total Market Shares ETF3.21M3.02%2.64K
Vanguard Total Stock Mkt Idx Inv3.18M2.99%1.80K
Fidelity Growth Company Fund2.66M2.51%-86.64K
Vanguard Small Cap Index2.57M2.42%2.10K
BB Biotech AG Ord2.42M2.28%-45.00K
BlackRock Event Driven Equity Instl1.83M1.72%553.75K
Vanguard Institutional Extnd Mkt Idx Tr1.50M1.41%6.29K
Vanguard Small Cap Growth Index Inv1.44M1.36%-6.64K

Recent Insider Transactions

DateNameRoleActivityValue
Dec 05, 2024Mates Sharon Chairman and CEOSell$129.91K
Dec 04, 2024Mates Sharon Chairman and CEOSell$2.01M
Dec 04, 2024Mates Sharon Chairman and CEOSell$2.37M
Dec 05, 2024Mates Sharon Chairman and CEOSell$4.22M
Nov 12, 2024Halstead Michael PresidentSell$149.79K

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1--
2024 Q4-9
2024 Q3-17
2024 Q2-3

ITCI Ownership FAQ

Who Owns Intra-Cellular Therapies?

Intra-Cellular Therapies shareholders are primarily institutional investors at 63.39%, followed by 3.22% insiders and 33.39% retail investors. The average institutional ownership in Intra-Cellular Therapies's industry, Specialty & Generic Drug Manufacturers Stocks, is 26.69%, which Intra-Cellular Therapies exceeds.

Who owns the most shares of Intra-Cellular Therapies?

Intra-Cellular Therapies’s largest shareholders are Fmr (11.08M shares, 10.47%), Vanguard group (9.72M shares, 9.19%), and Blackrock (6.32M shares, 6.53%). Together, they hold 26.19% of Intra-Cellular Therapies’s total shares outstanding.

Does Blackrock own Intra-Cellular Therapies?

Yes, BlackRock owns 6.53% of Intra-Cellular Therapies, totaling 6.32M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 432.97M$. In the last quarter, BlackRock decreased its holdings by -1.756M shares, a -21.74% change.

Who is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested?

Ally bridge group (ny) is Intra-Cellular Therapies’s biggest shareholder by percentage of total assets invested, with 10.58% of its assets in 147.75K Intra-Cellular Therapies shares, valued at 12.34M$.

Who is the top mutual fund holder of Intra-Cellular Therapies shares?

Fidelity Growth Compy Commingled Pl O is the top mutual fund holder of Intra-Cellular Therapies shares, with 3.69% of its total shares outstanding invested in 3.9M Intra-Cellular Therapies shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools